Biopharma
By
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3 clinical trial included…
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After Phase 3 Success?
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?
Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
